Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × gilteritinib × 90 days × Clear all

Phase

Phase 3 4 Phase 2 4 Phase 1/2 4 Phase 1 4 Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

Cisplatin 21 Magnetic Resonance Spectroscopy 19 Carboplatin 17 pembrolizumab 15 Specimen Handling 15 Gemcitabine 11 Pemetrexed 10 Paclitaxel 10 Nivolumab 10 Doxorubicin 10 Bevacizumab 10 atezolizumab 9 Radiotherapy 8 Platinum 8 1,2-diaminocyclohexaneplatinum II citrate 8 Radiation 7 Oxaliplatin 7 Docetaxel 7 Biopsy 7 Ipilimumab 6 Cyclophosphamide 6 venetoclax 5 Temozolomide 5 Rituximab 5 Radiotherapy, Intensity-Modulated 5 Immunoglobulin G 5 Etoposide 5 Drug Therapy 5 Disulfides 5 Dexamethasone 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07425808 2026-02-23

FIT-AML

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2/3 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡